Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies
WALTHAM, Mass.--(BUSINESS WIRE)--May 16, 2019--
Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company’s software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.
“As use of CGM grows, especially for people with type 2 diabetes, the missing element of insulin titration needs to be satisfied,” says Glytec’s Chief Medical Officer and diabetologist, Dr. Andrew S. Rhinehart. “This is where Glytec enters the picture. Our ability to seamlessly interact with glucose data that’s captured through CGM and use it to personalize insulin therapy is how patients are going to see real results, real improvements.”
Rhinehart adds: “Training tens of thousands of primary care providers on how to interpret and act on CGM data is a daunting proposition. Our platform can obviate that need, offering primary care providers the means to use CGM data to formulate timely and discrete dosing recommendations in a highly efficient, effective and scalable manner.”
The new USPTO patent allowance awarded to Glytec depicts the following key systems and methods [highly abridged and consolidated]:
“A lot of new diabetes technologies have been introduced over the past decade, but the percentage of people with type 2 diabetes who are at goal has not improved,” says Glytec’s Senior Vice President Research & Development, Robby Booth. “We believe a connected, virtual care model that capitalizes on these new technologies and makes the data truly actionable -- as described in this latest patent allowance as well as earlier patent allowances -- will serve as a catalyst for sustained A1C reduction, increased time in range and other outcomes improvements. CGM, smart insulin pens and insulin pumps all play an important role, and Glytec’s insulin titration and medication optimization capabilities are designed to support and enhance them whether they’re being used in an outpatient or inpatient setting.”
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System ® is the only FDA-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190516005189/en/
Joy Efron, 864-263-4160
Vice President Marketing
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: SURGERY TECHNOLOGY HARDWARE SOFTWARE PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS HOSPITALS MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH OTHER SCIENCE DIABETES FDA MEDICAL SUPPLIES NURSING SCIENCE MANAGED CARE
Copyright Business Wire 2019.
PUB: 05/16/2019 08:00 AM/DISC: 05/16/2019 08:01 AM